Members of our team had the opportunity to present a new poster abstract at the NASP 2024 Annual Meeting held October 6 – 9.

Authors

Casey Fitzpatrick, PharmD, BCPS | Sali Askar, PharmD Candidate | Andrew Wash, PharmD, PhD | Carly Giavatto, PharmD | Ana I. Lopez-Medina, PharmD, PhD | Lauren Bryant, PharmD, CDCES | Jessica Mourani, PharmD | Nick McDonald, PharmD | Elizabeth Carpenter, PharmD

Background

• Patients with uncontrolled type 2 diabetes mellitus (T2DM) are at greater risk for complications such as renal impairment, cardiovascular disease, and death.¹
• Given their beneficial effects on cardiovascular outcomes, weight, and hypoglycemic risk, sodium-glucose contransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and a dual glucose-dependent insulinotropic peptide/GLP-1 (GIP/GLP-1) RA have become mainstays in the treatment of T2DM.²
• SGLT2 inhibitors, GLP-1 RAs, and GIP/GLP-1 RAs are often not prescribed nor accessible to patients who could benefit from them.^3,4 Thus, opportunities exist to optimize their clinical use. ​
• The heath-system specialty pharmacy (HSSP) model embeds pharmacists within outpatient clinics where they can collaborate with prescribers to optimize therapeutic regimens.​

Objectives

• To describe the findings of an HSSP initiative aimed at optimizing medication regimens for patients with T2DM in alignment with clinical guideline recommendations.

Read about the team’s findings by downloading the outcomes study below.

​